NautaDutilh assisted Pfizer Inc. (PFE.US) with its issuance of euro-denominated notes, raising max EUR 3,3 billion.
This issuance marks Pfizer's first euro-denominated note in seven years and contributes to the growing trend of reverse Yankee note issuances. The notes have maturities of 4, 7, 12, and 20 years.
“It has been a pleasure for our team to assist Pfizer and its investors in this important note issuance. This transaction, Pfizer’s first euro-denominated note in seven years, reflects a carefully considered financing strategy in a dynamic market environment. By tapping into the European capital markets, Pfizer is not only diversifying its investor base and managing currency exposure, but also seizing the opportunity to secure long-term funding under favourable conditions.”
The team further consisted of Wijnand Bossenbroek, Brenno Baas, Lentle Nijs, Leanne Meurs and Eline Keuning.
About Pfizer
Pfizer Inc. is a global pharmaceutical company dedicated to the development and manufacture of healthcare products. With a rich history spanning over 170 years, Pfizer is committed to driving innovation and delivering breakthroughs that change patients' lives. The proceeds from this bond issuance will support Pfizer's ongoing efforts to diversify its funding sources and take advantage of favourable market conditions.